Arcutis adds Mirum CEO Chris Peetz to board of directors

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) said on July 15, 2026, its board of directors increased the authorized number of directors from nine to ten and appointed Christopher Peetz as a new board member.¹ His term as a Class III director runs until the company's 2029 annual meeting, subject to earlier resignation, disqualification, removal or death, and the board found him to qualify as independent under SEC and Nasdaq standards. Peetz has not been appointed to any board committee.¹

Peetz co-founded Mirum Pharmaceuticals, a commercial-stage biopharmaceutical company, and has led it as Chief Executive Officer since March 2019, having also served as President from November 2018 to January 2024. Earlier in his career, he was CEO of Flashlight Therapeutics from May 2017 to May 2019, served as CFO and head of corporate development at Tobira Therapeutics before its acquisition by Allergan plc in November 2016, held a VP role at Jennerex Biotherapeutics, worked in various positions at Onyx Pharmaceuticals (now Amgen), advised on mergers and acquisitions at LaSalle Corporate Finance (part of ABN AMRO), held roles at Abgenix and Solazyme, sat on the board of Alpine Immune Sciences until its 2024 sale to Vertex, and has been an entrepreneur-in-residence at Frazier Life Sciences since May 2017.¹ He holds an M.B.A. from Stanford Graduate School of Business and a B.S.B.A. in finance, international business, and French from Washington University in St. Louis.¹

As compensation, Peetz received an initial stock option grant for 21,486 shares of Arcutis common stock upon his appointment, and is eligible for a prorated annual equity award valued at approximately $350,000, split 65% options and 35% restricted stock units, along with a prorated cash retainer of $50,000¹. The initial option award vests in three equal annual installments starting on the anniversary of his appointment, while the prorated annual equity award vests just before the following annual meeting, contingent on continued board service.¹

The company stated there was no arrangement with any other party regarding Peetz's selection, no family relationships with existing directors or officers, and no related-party transactions requiring disclosure under SEC rules.¹